Sangamo Therapeutics, Inc.
7000 Marina Blvd
Tel: (510) 970-6000
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
613 articles with Sangamo Therapeutics, Inc.
Sangamo BioSciences, Inc. To Present Data From Its ZFP Therapeutic(TM) Programs At The 9th Annual Meeting Of The American Society of Gene Therapy
Data From Sangamo BioSciences, Inc.' Diabetic Neuropathy Program Published In Diabetes
Sangamo BioSciences, Inc. To Present At Two Upcoming Investor Conferences
Sangamo BioSciences, Inc. Presents Preclinical Data From ZFP Therapeutic For Age- Related Macular Degeneration
Sangamo BioSciences, Inc. Reports 2006 First Quarter Financial Results
Sangamo BioSciences, Inc. Announces First Quarter 2006 Conference Call And Webcast
The Day In Review: Pfizer Inc. Buys Another Biotech
Sangamo BioSciences, Inc. Announces First Clinical Results From Trial Of ZFP Therapeutic In Patients With Diabetic Neuropathy
Sangamo BioSciences, Inc. To Present At The BioCentury Future Leaders In The Biotech Industry Conference
Sangamo BioSciences, Inc. To Present At The 5th Annual JMP Securities Research Conference
Sangamo BioSciences, Inc. Licenses MaxCyte, Inc. Cell Loading Technology For ZFP Therapeutic Program For HIV/AIDS
Sangamo BioSciences, Inc. Reports 2005 Fourth Quarter And Year-End Financial Results
Sangamo BioSciences, Inc. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference 2006
Sangamo BioSciences, Inc. Announces HIV/CCR5 ZFP Therapeutic Data Presentation At 13th Conference On Retroviruses And Opportunistic Infections
Sangamo BioSciences, Inc. Announces Fourth Quarter And Year-End 2005 Conference Call And Webcast
Sangamo BioSciences, Inc. Announces Publication Of ZFP Therapeutic(TM) Data For Peripheral Artery Disease Program
Sangamo BioSciences, Inc. Announces Plans For Phase 2 Clinical Trial Of ZFP Therapeutic In Diabetic Neuropathy At JPMorgan Healthcare Conference
Sangamo BioSciences, Inc. To Present At 24th Annual JPMorgan Healthcare Conference
Sangamo BioSciences, Inc. Announces Expansion Of Research Collaboration Agreement With Pfizer Inc.
Sangamo BioSciences, Inc. Reports Success Using ZNPs To Fight Aids